Neuroinformatics specialists bridge the gap between neuroscience and data science, applying computational techniques to analyze and interpret complex neurological data. They develop software tools and algorithms to process large datasets obtained from neuroimaging, electrophysiological recordings, and genetic analyses. These specialists create models of brain activity and neural connectivity to better understand the underlying mechanisms of brain function and disorders. Their work plays a critical role in integrating data from various sources, including brain scans, genetic information, and behavioral data, creating comprehensive databases that can be used to study neurological diseases, brain disorders, and cognitive functions. Neuroinformatics specialists also contribute to the development of brain atlases and neural network models that help researchers visualize and understand the brain’s intricate structure and function. By utilizing big data, machine learning, and artificial intelligence, neuroinformatics specialists are advancing our ability to predict brain-related diseases and develop personalized treatment plans. Their research is essential for identifying biomarkers, improving diagnostic tools, and optimizing clinical trials for neurological treatments. Neuroinformatics also supports the emerging field of precision medicine, enabling clinicians to tailor therapies based on individual patient data and genetic profiles. These specialists collaborate closely with neuroscientists, data scientists, and clinicians to ensure that their findings have practical applications in medical settings.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States